Distinct Metastatic Phenotypes Between Early-onset and Late-onset Colorectal Cancer

September 11, 2023 updated by: LI XIN-XIANG, Fudan University

Integrated Analysis of Multi-center Cohorts and Bulk RNA-sequencing Data Reveal Distinct Metastatic Phenotypes Between Early-onset and Late-onset Colorectal Cancer

The clinical and pathological features of early-onset colorectal cancer (EOCRC) differ from those of late-onset colorectal cancer (LOCRC). Our research aims to thoroughly elucidate the distinctions between them by analyzing clinical prognosis, metastatic patterns, gene expression, and genomic mutation profiles. Our deliberation will uncover latent strategies for personalized therapeutic of both EOCRC and LOCRC.

Study Overview

Study Type

Observational

Enrollment (Actual)

15244

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with colorectal cancer hospitalized in Fudan university Shanghai cancer center.

Description

Inclusion Criteria:

  • The initial diagnosis of colonoscopy and pathology belongs to colorectal cancer;
  • Patients should sign an informed consent form after fully understanding the purpose, procedures and potential risks of the study, indicating their voluntary participation in the research.

Exclusion Criteria:

  • Patients with obvious local or systemic severe infection;
  • Acute abdomen: intestinal obstruction, peritonitis, intestinal perforation;
  • Have a systemic underlying disease that has not been controlled, or is unstable;
  • Patients with poor physical fitness or serious other organic diseases who cannot tolerate anesthesia and surgery;
  • Women during pregnancy, perinatal and lactation;
  • Patients with severe mental disorders (such as schizophrenia, bipolar disorder, etc.) or patients who are mentally incapable or unable to understand the requirements for participation in the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
EOCRC
Patients aged<50 with colorectal cancer between 2008 and 2018 in Fudan university Shanghai cancer center.
Patients enrolled in these 2 cohorts all received standardized treatment of colorectal cancer.
IOCRC
Patients aged between 50 to 70 with colorectal cancer between 2008 and 2018 in Fudan university Shanghai cancer center.
Patients enrolled in these 2 cohorts all received standardized treatment of colorectal cancer.
LOCRC
Patients aged between≥70 with colorectal cancer between 2008 and 2018 in Fudan university Shanghai cancer center.
Patients enrolled in these 2 cohorts all received standardized treatment of colorectal cancer.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
OS
Time Frame: 5 years after intervention
overall survival
5 years after intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2008

Primary Completion (Actual)

December 31, 2018

Study Completion (Actual)

June 30, 2023

Study Registration Dates

First Submitted

September 11, 2023

First Submitted That Met QC Criteria

September 11, 2023

First Posted (Actual)

September 15, 2023

Study Record Updates

Last Update Posted (Actual)

September 15, 2023

Last Update Submitted That Met QC Criteria

September 11, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Early-onset Colorectal Cancer

Clinical Trials on standardized treatment

3
Subscribe